TY - JOUR
T1 - Pancreatic enzyme replacement therapy in patients with exocrine pancreatic insufficiency due to chronic pancreatitis
T2 - A 1-year disease management study on symptom control and quality of life
AU - D'Haese, Jan G.
AU - Ceyhan, Güralp O.
AU - Demir, Ihsan Ekin
AU - Layer, Peter
AU - Uhl, Waldemar
AU - Löhr, Matthias
AU - Rychlik, Reinhard
AU - Pirilis, Konstantinos
AU - Zöllner, York
AU - Gradl, Birgit
AU - Foerster, Douglas
AU - Möbius, Julia
AU - Henniges, Friederike
AU - Friess, Helmut
PY - 2014/8
Y1 - 2014/8
N2 - Objective: Exocrine pancreatic insufficiency (EPI) is frequent in patients with chronic pancreatitis (CP). This 1-year, prospective, multicenter, observational, disease management study aimed to assess symptom improvement and quality of life in patients with CP with EPI who were receiving pancreatic enzyme replacement. Methods: Patients with CP and chronic EPI were either assigned to cohort 1 that consisted of patients already taking pancreatin (Kreon; Abbott Arzneimittel GmbH, Hannover, Germany) or cohort 2 that consisted of patients with newly diagnosed EPI without prior pancreatic enzyme treatment. Symptoms were documented, and quality of life was assessed using the gastrointestinal quality of life index (GIQLI) at baseline, 6 months, and 1 year. Results: A total of 294 patients were evaluated (cohort 1, n = 206; cohort 2, n = 88). The proportion of patients experiencing gastrointestinal symptoms and recurrent pain after 1 year was significantly reduced in both cohorts (P < 0.001). The alleviation of symptoms was reflected in GIQLI score improvements at 1 year in both cohorts (P < 0.001), independent of CP severity and etiology. Improvements in GIQLI score were more pronounced in cohort 2 (P < 0.001). Conclusions: Pancreatin demonstrated symptom relief and improvement in quality of life in patients with CP-related EPI in this disease management study.
AB - Objective: Exocrine pancreatic insufficiency (EPI) is frequent in patients with chronic pancreatitis (CP). This 1-year, prospective, multicenter, observational, disease management study aimed to assess symptom improvement and quality of life in patients with CP with EPI who were receiving pancreatic enzyme replacement. Methods: Patients with CP and chronic EPI were either assigned to cohort 1 that consisted of patients already taking pancreatin (Kreon; Abbott Arzneimittel GmbH, Hannover, Germany) or cohort 2 that consisted of patients with newly diagnosed EPI without prior pancreatic enzyme treatment. Symptoms were documented, and quality of life was assessed using the gastrointestinal quality of life index (GIQLI) at baseline, 6 months, and 1 year. Results: A total of 294 patients were evaluated (cohort 1, n = 206; cohort 2, n = 88). The proportion of patients experiencing gastrointestinal symptoms and recurrent pain after 1 year was significantly reduced in both cohorts (P < 0.001). The alleviation of symptoms was reflected in GIQLI score improvements at 1 year in both cohorts (P < 0.001), independent of CP severity and etiology. Improvements in GIQLI score were more pronounced in cohort 2 (P < 0.001). Conclusions: Pancreatin demonstrated symptom relief and improvement in quality of life in patients with CP-related EPI in this disease management study.
KW - disease management research
KW - exocrine pancreatic insufficiency
KW - gastrointestinal quality of life index
KW - Kreon/Creon
KW - pancreatic enzyme replacement
UR - http://www.scopus.com/inward/record.url?scp=84904402016&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000131
DO - 10.1097/MPA.0000000000000131
M3 - Article
C2 - 24717829
AN - SCOPUS:84904402016
SN - 0885-3177
VL - 43
SP - 834
EP - 841
JO - Pancreas
JF - Pancreas
IS - 6
ER -
